Incyte Corporation maintained revenue guidance for 2024. For the year the company expects Jakafi net product revenues of $2,690 million to $2,750 million. The company expects other Hematology/Oncology net product revenues $325 million to $360 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
57.16 USD | +0.19% | +6.55% | -9.20% |
May. 13 | Equities Close Mixed as Markets Weigh Consumer Inflation Survey | MT |
May. 13 | Equities Close Mixed as Markets Parse Consumer Inflation Survey | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.92% | 12.81B | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-8.65% | 33.03B | |
+55.32% | 24.68B | |
-16.47% | 15.12B | |
-12.11% | 11.79B | |
-43.61% | 11.64B | |
+7.79% | 8.9B | |
-7.72% | 8.22B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Corporation Maintains Revenue Guidance for 2024